Types of Allergy Shots: 8-Product Comparison Matrix — SCIT, Biologics, Steroids, Epinephrine
At least eight different products are commonly called 'allergy shots' — and only two of them (SCIT and SLIT) actually retrain the immune system. The matrix: (1) SCIT (subcutaneous immunotherapy) — disease-modifying, Cochrane SMD −0.73; (2) SLIT tablets (Grastek/Oralair/Ragwitek/Odactra) — FDA-approved disease-modifying oral; (3) SLIT drops (off-label); (4) Xolair (anti-IgE biologic); (5) Dupixent (anti-IL-4Rα); (6) Tezspire (anti-TSLP); (7) Depot steroids (symptomatic only, discouraged); (8) Epinephrine (emergency rescue). VIT (venom immunotherapy) is a ninth distinct class.
8 peer-reviewed sources
Eight product classes are called 'allergy shots': SCIT and SLIT are disease-modifying; Xolair, Dupixent, and Tezspire are biologics treating allergic disease without inducing allergen tolerance; depot steroids are symptomatic; epinephrine is emergency rescue. Only SCIT and SLIT retrain allergen-specific immunity.
The essentials
There are at least eight different products that a patient might encounter under the label 'allergy shot' — and the clinical distinctions between them are fundamental. SCIT and SLIT are allergen-specific immunotherapy that retrain the immune system to tolerate specific allergens. Biologics (Xolair, Dupixent, Tezspire) treat allergic diseases by blocking inflammatory mediators but do not produce allergen-specific tolerance. Depot corticosteroids suppress symptoms temporarily. Epinephrine reverses anaphylaxis but does not prevent it. Venom immunotherapy (VIT) is its own separate product class.
Curex's at-home IgE testing with board-certified allergist review identifies which specific allergens drive a patient's symptoms — the diagnostic step that determines whether allergen-specific immunotherapy (SCIT or SLIT) is even the right product class, or whether the patient's clinical picture points to biologics, symptomatic therapy, or environmental management.
The critical clinical-clarity principle: SCIT and SLIT are the ONLY products that produce allergen-specific tolerance — the reprogramming of T-cell and B-cell memory to ignore the trigger allergen. All other products in this matrix either block inflammatory pathways downstream (biologics), suppress the inflammatory response temporarily (steroids), or reverse acute anaphylaxis (epinephrine). Understanding this distinction is what allows a patient to ask the right question: "Which problem am I actually trying to solve?"
Product 1 — SCIT (subcutaneous immunotherapy): a 3–5 year course of allergen-extract injections, traditionally given in-clinic but now available at home for eligible maintenance patients. Curex delivers the identical immunotherapy as one weekly self-administered shot for $129/month — a personalized serum sterile-compounded to USP <797> standards, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand. Uses FDA-licensed allergen extracts (19 standardized, plus non-standardized). Cochrane Calderón 2007 (51 RCTs, 2,871 patients): symptom SMD −0.73, medication SMD −0.57. Durham 1999 NEJM: 3 additional years of remission after stopping a 3–4 year course. Cox 2011 PP3 schedules: roughly 39 Year-1 visits and ~14 maintenance visits/yr in the traditional clinic model, with a 30-minute observation after each injection. Pediatric asthma prevention: PAT study (Möller 2002, Jacobsen 2007): OR 4.6 for asthma-free at 10 years.
Product 2 — FDA-approved SLIT tablets: Grastek (timothy grass, ALK, ages 5–65), Oralair (5-grass, Stallergenes, ages 5–65), Ragwitek (short ragweed, Merck, ages 5–65 after April 2021 expansion), Odactra (house dust mite, Merck, ages 5–65 after 2025 label expansion). All four: daily sublingual, not injected; boxed warnings for anaphylaxis; supervised first dose required; epinephrine co-prescription required. Disease-modifying via same allergen-specific tolerance mechanism as SCIT.
Product 3 — SLIT drops (compounded, off-label): liquid sublingual formulations prescribed for home use. Not FDA-approved as a product class; prescribed under the evidence base from SCIT and SLIT tablet RCTs. Evidence extrapolated from Alvarez-Cuesta 2007 (cat SLIT, Allergy 2007;62:810-817) and Mosbech 2014 (HDM SLIT-tablet). Same immunologic mechanism as SCIT.
Product 4 — Xolair (omalizumab): anti-IgE monoclonal antibody (subcutaneous, q2–4 weeks based on serum IgE + weight). FDA approved: allergic asthma (2003); chronic spontaneous urticaria; CRSwNP; food allergy (fourth indication, February 16, 2024 — OUtMATCH trial: 67% of omalizumab-treated patients tolerated ≥600 mg peanut protein vs 7% placebo; Wood RA et al., NEJM 2024;390:889-899). Does NOT produce allergen-specific tolerance — blocks IgE binding at all Fc receptors, reducing mast-cell and basophil reactivity broadly.
Product 5 — Dupixent (dupilumab): anti-IL-4Rα fully human monoclonal (subcutaneous q2 weeks after loading). FDA approved: moderate-to-severe atopic dermatitis (March 2017); eosinophilic/OCS-dependent asthma (October 2018); CRSwNP; eosinophilic esophagitis (EoE); prurigo nodularis; COPD with eosinophilic phenotype. Blocks IL-4 and IL-13 signaling. Does NOT produce allergen tolerance.
Product 6 — Tezspire (tezepelumab-ekko): anti-TSLP human monoclonal (210 mg subcutaneous q4 weeks). FDA approved December 17, 2021 for severe asthma in patients ≥12 years. First biologic not requiring a specific phenotype (eosinophilic, allergic, or biomarker-defined). NAVIGATOR Phase 3 pivotal trial. Does NOT produce allergen tolerance.
Product 7 — Depot corticosteroids (Kenalog-40, Depo-Medrol): triamcinolone acetonide (Kenalog-40, FDA-approved February 1, 1965) and methylprednisolone acetate (Depo-Medrol) IM injections. Depo-Medrol FDA label: "an intramuscular dose of 80 to 120 mg may be followed by relief of coryzal symptoms within six hours persisting for several days to three weeks." NOT immunotherapy, NOT disease-modifying. AAAAI/ACAAI rhinitis Practice Parameter discourages single administration for routine seasonal AR; contraindicates recurrent administration (HPA-axis suppression risk).
Product 8 — Epinephrine (EpiPen, Auvi-Q, neffy, generics): emergency anaphylaxis reversal only. EpiPen first FDA-approved 1987; Teva generic 2018; Auvi-Q (2012, distinctive voice-guided device); neffy (epinephrine nasal spray, ARS Pharmaceuticals, FDA-approved August 9, 2024, 2 mg dose for patients ≥4 yr and ≥15 kg; pediatric 1 mg dose approved March 5, 2025). WAO recommends IM epinephrine 0.01 mg/kg (max 0.5 mg adults / 0.3 mg children) into mid-anterolateral thigh as first-line for anaphylaxis. Not a preventive treatment.
Product 9 — Venom immunotherapy (VIT): separate FDA-approved class using purified Hymenoptera venoms (honey bee, yellow jacket, paper wasp, yellow hornet, white-faced hornet + mixed vespid). Cochrane Boyle 2012 (PMID 23076950): 2.7% systemic re-sting rate in VIT-treated vs 39.8% untreated (RR 0.10). Hunt 1978 NEJM proved venom superiority over whole-body extract. Must be administered in-office.
Palforzia (peanut oral immunotherapy, FDA-approved January 31, 2020 for ages 4–17) is a tenth product in the allergen-immunotherapy space that is sometimes confused with SCIT. Commercial discontinuation was announced effective July 31, 2026 (final new starts January 30, 2026) — a voluntary business decision unrelated to safety or efficacy. Palforzia is OIT (oral immunotherapy), not SCIT.
How allergy shots retrain your immune system
Only SCIT and SLIT produce allergen-specific immune tolerance — the fundamental distinction from all other products in this matrix. The mechanism: graduated allergen exposure shifts immunity from IgE-Th2 (allergic) to IgG4-Treg (tolerogenic) over 3–5 years. All other products in this matrix work downstream of allergen sensitization: biologics block IgE, IL-4/13, or TSLP signaling; steroids suppress the entire inflammatory cascade; epinephrine reverses acute anaphylaxis by activating adrenergic receptors.
Allergen-Specific (SCIT/SLIT): Immune Reprogramming
Escalating allergen doses expand FOXP3+ Tregs and IL-10-producing Tr1 cells, switching B-cell antibody production from IgE to IgG4. Allergen-specific IgG4 rises 10- to 100-fold, blocking IgE-FcεRI cross-linking on mast cells. Disease modification persists after stopping because long-lived IgG4-producing plasma cells survive in bone marrow niches for years.
Biologics (Xolair/Dupixent/Tezspire): Pathway Blockade
Xolair binds free IgE, preventing FcεRI loading of mast cells and basophils — reducing reactivity to all allergens broadly. Dupixent blocks IL-4Rα signaling, reducing Th2 cytokine-driven inflammation in skin, lung, and GI mucosa. Tezspire blocks TSLP — an upstream epithelial cytokine — reducing the initial signal that activates dendritic cells and initiates Th2 differentiation. None produce allergen tolerance.
Depot Steroids / Epinephrine: Symptomatic Rescue
Depot corticosteroids (Kenalog-40, Depo-Medrol) suppress IgE-driven inflammation broadly via glucocorticoid receptor signaling — days to weeks of relief, no immune reprogramming. Epinephrine reverses anaphylaxis acutely by binding α and β adrenergic receptors to constrict mucosal vasodilation, restore cardiovascular tone, and relax bronchospasm. No preventive or disease-modifying effect.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Efficacy comparison across the types of allergy shots — organized by product class to support product-selection decisions.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
The eight-product comparison matrix for types of allergy shots — categorized by mechanism, FDA status, disease-modification, and practical access.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (subcutaneous immunotherapy) | |||||
SLIT tablets (Grastek/Oralair/Ragwitek/Odactra) | |||||
SLIT drops (compounded, off-label) | |||||
Xolair (omalizumab, anti-IgE biologic) | |||||
Dupixent (dupilumab, anti-IL-4Rα biologic) | |||||
Tezspire (tezepelumab-ekko, anti-TSLP biologic) | |||||
Depot corticosteroids (Kenalog-40 / Depo-Medrol) | |||||
Epinephrine (EpiPen / Auvi-Q / neffy) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For patients where allergen-specific immunotherapy is appropriate, Curex offers at-home subcutaneous immunotherapy — the disease-modifying SCIT shot itself, not a substitute — as one weekly self-administered injection for $129/month. The personalized serum is sterile-compounded to USP <797> standards; a board-certified allergist confirms candidacy, a prescribed epinephrine auto-injector is confirmed on hand, and the first dose and every dose change are supervised live over Zoom, so eligible maintenance patients complete the same multi-year course without the clinic-visit burden.
See if at-home shots are right for youFrequently asked questions
What is the difference between allergy shots and biologics like Xolair?
SCIT (allergy shots) produce allergen-specific immune tolerance by retraining allergen-reactive T cells and B cells — the same cells that drive the allergic response — toward a non-reactant regulatory phenotype. Allergen-specific IgG4 rises 10- to 100-fold; IgE-driven mast-cell reactivity declines over years. Benefits persist 3–12 years after stopping. Xolair (omalizumab) is an anti-IgE monoclonal antibody that binds free IgE, preventing it from loading onto mast-cell FcεRI receptors — reducing reactivity to all allergens broadly, not specifically. It is effective while taken but produces no lasting tolerance; symptoms return when discontinued. They are complementary, not competing, products for different clinical scenarios.
Are allergy shots the same as Dupixent?
No — SCIT (allergy shots) and Dupixent (dupilumab) are entirely different product classes with different mechanisms, indications, and target populations. SCIT delivers allergen-specific immunotherapy (subcutaneous injections of allergen extract) producing allergen-specific tolerance over 3–5 years. Dupixent (anti-IL-4Rα monoclonal, FDA-approved 2017 for atopic dermatitis, 2018 for asthma) blocks IL-4 and IL-13 signaling — the Th2 cytokines driving eosinophilic/allergic inflammation. Dupixent does not produce allergen tolerance and requires ongoing biweekly injections indefinitely. Some patients with severe allergic disease have BOTH allergen-specific SCIT and a biologic like Dupixent as part of their treatment plan.
What is the 'allergy steroid shot' and why do allergists discourage it?
The 'allergy steroid shot' is most commonly a single intramuscular injection of triamcinolone acetonide (Kenalog-40, FDA-approved February 1, 1965) or methylprednisolone acetate (Depo-Medrol). It delivers symptomatic anti-inflammatory relief lasting several days to three weeks (Depo-Medrol FDA label) by suppressing the entire inflammatory cascade via glucocorticoid receptor signaling. The AAAAI/ACAAI rhinitis Practice Parameter discourages single parenteral steroid administration for routine seasonal AR and explicitly contraindicates recurrent use because: (1) it is not disease-modifying; (2) recurrent depot corticosteroid suppresses the hypothalamic-pituitary-adrenal axis; (3) superior disease-modifying alternatives (SCIT, SLIT) exist.
What is neffy and when was it approved?
Neffy (epinephrine nasal spray, ARS Pharmaceuticals) is FDA-approved for the emergency treatment of allergic reactions including anaphylaxis. The 2 mg dose was FDA-approved on August 9, 2024 for patients ≥4 years and ≥15 kg; a pediatric 1 mg dose was subsequently approved on March 5, 2025. Neffy is an alternative to injection-based epinephrine auto-injectors (EpiPen, Auvi-Q) for patients who have difficulty with or refuse needle-based products. It is emergency-rescue only — not immunotherapy, not disease-modifying, not a substitute for allergen immunotherapy.
Is Palforzia an allergy shot?
No — Palforzia (peanut allergen powder-dnfp, Aimmune) is oral immunotherapy (OIT) for peanut allergy, not a shot. It was FDA-approved on January 31, 2020 for ages 4–17. It is taken orally by mixing the powder into food in escalating doses. Palforzia is not SCIT (no injection) and is not environmental aeroallergen immunotherapy (peanut is a food allergen, not an aeroallergen). Important time-sensitive update: Palforzia commercial discontinuation was announced effective July 31, 2026, with no final new patient starts after January 30, 2026 — this is a voluntary business decision unrelated to safety or efficacy. Patients currently on Palforzia should contact their allergist for transition planning.
What type of allergy shot is best for seasonal allergies?
For seasonal allergic rhinitis driven by pollen, SCIT is the most evidence-based disease-modifying option (Cochrane Calderón 2007, 51 RCTs, SMD −0.73). FDA-approved SLIT tablets (Grastek for timothy grass, Oralair for 5-grass, Ragwitek for short ragweed) are disease-modifying oral alternatives for patients who prefer home dosing over in-clinic injections — but they cover only specific allergens. Biologics (Xolair, Dupixent) are appropriate for seasonal allergic rhinitis only when combined with asthma, CRSwNP, or other biologic-indicated comorbidities. Depot steroids and epinephrine are not appropriate preventive or disease-modifying options for seasonal allergies.
What type of allergy shot prevents bee sting anaphylaxis?
Venom immunotherapy (VIT) is the only product that prevents bee sting anaphylaxis. VIT uses purified Hymenoptera venom extracts (honey bee, yellow jacket, paper wasp, yellow hornet, white-faced hornet + mixed vespid). Cochrane Boyle 2012 (PMID 23076950) documented 2.7% systemic re-sting reaction rate in VIT-treated patients versus 39.8% in untreated controls. Environmental SCIT (pollen/dust mite/dander) does not protect against insect venom reactions — they are separate product classes targeting different IgE sensitizations. VIT must be administered in-office under 30-minute observation. Epinephrine auto-injectors are the acute rescue for sting reactions but do not prevent subsequent reactions.
Can I combine allergy shots with Xolair or Dupixent?
Combination of SCIT with biologics is an evolving area. Pre-treatment Xolair (omalizumab) to reduce systemic-reaction risk during SCIT build-up has been studied in patients with high-risk profiles (very high IgE, concurrent severe asthma, multiple allergen sensitizations) and is practiced at specialized centers, though not yet standard protocol. SCIT plus Dupixent is practiced for patients with both seasonal AR and moderate-to-severe AD or asthma — the biologic addresses the Th2 inflammatory phenotype while SCIT builds allergen-specific tolerance. The combination is typically managed by a specialist allergist/immunologist with experience in both product classes.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Shot: SCIT Guide for Patients | Curex
An allergy shot is subcutaneous immunotherapy (SCIT) — a 3-to-5-year course. Cochrane 51 RCTs found SMD -0.73. Learn how it works, costs, and who qualifies.
Read moreAllergy Therapy: All Treatments Explained | Curex
Allergy therapy spans pharmacotherapy, SCIT shots, SLIT drops, and biologics. Only SCIT and SLIT modify the underlying disease. Learn which therapy fits your situation.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.